AKU · Akumin Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $180.62M | $184.84M | $187.59M | - | $186.60M | $69.50M | $186.26M | - | $108.18M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $222.81M | $249.32M | $185.34M | - | $195.06M | $63.07M | $183.22M | - | $59.60M | - |
| D&A | $20.94M | $35.02M | $22.99M | - | $25.08M | $25.20M | $4.49M | - | $11.29M | - |
| Operating Income | ($42.18M) | ($64.48M) | $2.25M | - | ($8.45M) | ($2.61M) | $3.05M | - | $3.61M | - |
| Interest Expense | $33.87M | $31.16M | $30.70M | - | $29.68M | $29.29M | $8.37M | - | $8.96M | - |
| Income Tax | ($80.0K) | ($1.58M) | $874.0K | - | $12.04M | $6.0K | $563.0K | - | ($473.0K) | - |
| Net Income | ($82.39M) | ($96.65M) | ($35.15M) | - | ($53.87M) | ($30.47M) | ($30.81M) | - | ($1.34M) | - |
| EPS - Basic | ($0.90) | ($1.07) | ($0.39) | - | ($0.02) | ($0.34) | - | - | - | - |
| EPS - Diluted | ($0.90) | ($1.07) | ($0.35) | - | ($0.02) | ($0.10) | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.64M | $37.97M | $45.40M | $59.42M | $59.36M | $38.45M | $40.24M | $48.42M | $27.36M | $44.40M |
| Accounts Receivable | $118.10M | $115.79M | $114.70M | $114.17M | $112.38M | $126.14M | $126.48M | $121.53M | $135.21M | $91.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $57.06M | $43.58M | $25.46M | $36.62M | $27.70M | $34.33M | - | - | $41.04M | $20.40M |
| Current Assets | $174.20M | $172.54M | $176.52M | $191.94M | $189.33M | $180.80M | $180.14M | $185.16M | $206.13M | $139.47M |
| Total Assets | $1.59B | $1.64B | $1.72B | $1.77B | $1.81B | $1.86B | $1.89B | $1.92B | $1.95B | $718.68M |
| Current Liabilities | $1.45B | $174.78M | $162.36M | $168.52M | $167.30M | $167.10M | $162.06M | $164.18M | $172.00M | $51.94M |
| Long-term Debt | $40.27M | $1.27B | $1.26B | $1.25B | $1.24B | $1.22B | $1.21B | $1.20B | $389.58M | $401.13M |
| Total Liabilities | $1.68B | $1.64B | $1.62B | $1.62B | $1.61B | $1.60B | $1.60B | $1.60B | $1.59B | $578.95M |
| Stockholders' Equity | ($261.11M) | ($179.21M) | ($82.98M) | ($48.20M) | ($7.52M) | $45.79M | $75.48M | $105.19M | $148.72M | $134.21M |
| Retained Earnings | ($494.37M) | ($411.99M) | ($315.33M) | ($280.19M) | ($238.57M) | ($184.70M) | ($154.24M) | ($123.42M) | ($91.70M) | ($26.76M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $3.30M | - | - | - | $7.75M | - | - | - |
| Investing Cash Flow | - | - | ($2.18M) | - | - | - | ($9.88M) | - | - | - |
| Financing Cash Flow | - | - | ($15.15M) | - | - | - | $76.34M | - | - | - |
| CapEx | - | - | $2.51M | - | - | - | $1.17M | - | - | - |
| Free Cash Flow | - | - | $796.0K | - | - | - | $6.58M | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -23.4% | -34.9% | 1.2% | - | -4.5% | -3.8% | 1.6% | - | 3.3% | - |
| EBITDA margin | -11.8% | -15.9% | 13.5% | - | 8.9% | 32.5% | 4.0% | - | 13.8% | - |
| Net margin | -45.6% | -52.3% | -18.7% | - | -28.9% | -43.8% | -16.5% | - | -1.2% | - |
| Free cash flow margin | - | - | 0.4% | - | - | - | 3.5% | - | - | - |
| FCF / Net income | - | - | -0.02 | - | - | - | -0.21 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.2% | -5.9% | -2.0% | - | -3.0% | -1.6% | -1.6% | - | -0.1% | - |
| Return on equity | 31.6% | 53.9% | 42.4% | - | 716.6% | -66.5% | -40.8% | - | -0.9% | - |
| Return on invested capital | - | -4.7% | 0.2% | - | -0.5% | -0.2% | 0.2% | - | 0.5% | - |
| Liquidity | ||||||||||
| Current ratio | 0.12 | 0.99 | 1.09 | 1.14 | 1.13 | 1.08 | 1.11 | 1.13 | 1.20 | 2.69 |
| Quick ratio | 0.12 | 0.99 | 1.09 | 1.14 | 1.13 | 1.08 | 1.11 | 1.13 | 1.20 | 2.69 |
| Cash ratio | 0.02 | 0.22 | 0.28 | 0.35 | 0.35 | 0.23 | 0.25 | 0.29 | 0.16 | 0.85 |
| Leverage | ||||||||||
| Debt / Equity | -0.15 | -7.10 | -15.22 | -26.03 | -165.23 | 26.66 | 16.03 | 11.39 | 2.62 | 2.99 |
| Debt / Assets | 0.03 | 0.78 | 0.73 | 0.71 | 0.69 | 0.66 | 0.64 | 0.62 | 0.20 | 0.56 |
| Debt / EBITDA | - | - | 50.02 | - | 74.70 | 54.04 | 160.52 | - | 26.15 | - |
| Interest coverage | -1.2x | -2.1x | 0.1x | - | -0.3x | -0.1x | 0.4x | - | 0.4x | - |
| Equity multiplier | -6.09 | -9.13 | -20.76 | -36.62 | -240.65 | 40.65 | 25.06 | 18.24 | 13.13 | 5.36 |
| Liabilities / Assets | 1.06 | 1.00 | 0.94 | 0.92 | 0.89 | 0.86 | 0.85 | 0.83 | 0.81 | 0.81 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.11 | 0.11 | - | 0.10 | 0.04 | 0.10 | - | 0.06 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 239d | 229d | 223d | - | 220d | 663d | 248d | - | 456d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -3.2% | 166.0% | 0.7% | - | 72.5% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -399.2% | -2373.3% | -26.2% | - | - | - | - | - | - | - |
| Net income growth (YoY) | -52.9% | -217.2% | -14.1% | - | -3929.2% | - | - | - | - | - |
| EPS growth (YoY) | -4400.0% | -970.0% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -87.9% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3373.1% | - | - | - | - | - | - | -21.6% | - | -12.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$421.08M totalRadiology$374.40M · 88.9%
Oncology$46.68M · 11.1%
Product / service
$416.07M totalCommercial Revenue$226.84M · 54.5%
Hospital And Healthcare Providers$118.49M · 28.5%
Medicare Revenue$51.24M · 12.3%
Other Patient Revenue$11.50M · 2.8%
Medicaid Revenue$8.00M · 1.9%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing AKUMIN INC. against the 5 most active filers in the same SIC group.